Efficacy Study of Atorvastatin in Pelvic Pain Relief in Women With Endometriosis

Inclusion Criteria: * informed written consent * premenopausal women aged 18-45 * clinical signs and symptoms of endometriosis for minimum 3 months with endometriosis confirmed at laparoscopy or laparotomy within last 4 months - 5 years (preferably with histological confirmation) * pain symptoms of moderate intensity (dysmenorrhoea + dyspareunia + nonmenstrual pelvic pain \> 6 points on Biberoglu \& Behrman scale \[1981\]) * no clinical signs of sexually transmitted disease Exclusion Criteria: * cancer of the ovary, adrenals, endometrium, uterine cervix, breasts * pregnancy or lactation * unexplained uterine/cervical bleeding * hormonal therapy within last 3 months (for GnRH analogs 6 months) * irregular menses (\> 35 days) or secondary amenorrhoea (\>3 months) * other chronic disease affecting pelvic or abdominal cavity (including PID, ulcerating colitis , Crohn's disease, recurrent interstitial cystitis) * sexually transmitted disease (gonorrhoea, Chlamydia) * uncontrolled diabetes mellitus type I or II, VTE or other contraindications to medicine used in the study * chronic therapy with CYP3A4 inhibitors (including ketoconazole, erythromycin and others)